Introduction
gated apo E genotypes and serum lipid and lipoprotein were calculated using the Friedewald formula. In some cases levels in subjects undergoing continuous ambulatory where fasting triglyceride levels were >4 mmol/l, plasma peritoneal dialysis (CAPD).
lipoproteins levels were assayed using a combination of ultracentrifugation and precipitation as outlined in detail elsewhere [ 27] . The remaining plasma and serum samples Experimental procedure were immediately frozen and kept at −70°C.
Apo E genotyping was carried out on genomic DNA Subjects originating from leukocytes in venous blood samples drawn into EDTA-containing tubes. The genomic DNA was preFifty-one adult patients with end-stage renal disease under-pared using Qiagen Blood & Cell Culture DNA Midi Kits going CAPD at the Renal Medicine Clinic at Huddinge (Qiagen GmbH, Hilden, Germany). The procedure utilized University Hospital, were recruited to participate in the the minisequencing technique as adapted for apo E genotypstudy. The cause of renal failure was in 19 cases glomerulo-ing [ 29] , modified to allow easy detection and rapid handling nephritis, in 11 cases diabetic nephropathy, in nine cases of multiple samples without the use of radioactivity [30] . In interstitial nephritis, in six cases other diseases, and six the present study, the method was modified to allow the subjects suffered from end-stage renal disease of unknown simultaneous evaluation of all three apo e allelic variants cause. On average the duration of CAPD treatment was (AffiGene Apo E Kit, Sangtec Medical, Stockholm, Sweden). 11±10 months (range 1-54 months). Nine of the subjects Briefly, the minisequencing procedure was carried out in had previously been treated with haemodialysis prior to streptavidin-coated microtitre wells. A 203-bp fragment of CAPD treatment, and of these subjects, none had been on the apo E gene, including the sites for codons 112 and 158 CAPD treatment for less than 6 months. The CAPD regimen (ApoE Primer Kit, Sangtec Medical, Stockholm, Sweden) had a prescribed dialysate volume of 6 litres in seven subjects, was amplified. The downstream primer was biotinylated, 8 litres in 25 subjects, 10 litres in eight subjects, and 12.5 enabling the anticoding strand of the PCR product to attach litres in two subjects. Nine patients were treated with auto-to the coated wells. Two 20-mer 'detection primers' were mated peritoneal dialysis with an average prescribed daily annealed to the attached strands, and the DNA polymerase dialysate volume of 21 litres (range 12.5-25 litres). Four of extension reaction was carried out with dinitrophenyl (DNP)-the patients were treated with hypolipidaemic drugs, in three labelled mononucleotides (DNP-T or DNP-C ). For each cases simvastatin (10-20 mg/day) and in one case bezafibrate polymorphic site, two wells with the amplified strand were ( 200 mg/day). The presence of cardiovascular disease was used, adding DNP-T to one well, and DNP-C to the other defined as previous verified myocardial infarction, or angina well. The wells were rinsed, and anti-DNP-antibodies, conpectoris, with a typical clinical presentation or verified jugated with alkaline phosphatase, were added. The bound through a positive stress test. The clinical characteristics of antibodies were detected using an ELISA procedure. Apo E the patient population is summarized in Table 1 . Results genotypes were determined based on the patterns obtained were compared with a previously characterized healthy con-with the different DNP-antibody reactions. The automated trol group, consisting of 244 men and 163 women, aged procedure allowed 22 samples to be processed in 4 h. 17-86 years [17 ] .
Statistical analysis Analytical procedures
Data are presented as means±SD. For analysis of apo E All blood samples were drawn between 0800 hours and 0900 genotypes, the number of a given allele, e.g. e3, in the pair hours after an overnight fast. Samples were drawn into tubes of alleles can be 0,1 or 2, corresponding to individual relative with or without EDTA. Plasma or serum was separated frequencies of 0, 50 or 100% respectively. A carrier of immediately by centrifugation in the cold at 2000 r.p.m. for a specific e allele was defined as a subject carrying the E4, 20 min. Phenylmethylsulphonyl fluoride was added to all E3 or E2 phenotype in homo-or heterozygous form. samples at a final concentration of 0.01 mmol/l. Unless Comparisons between groups were carried out with a twoimmediately analysed, the plasma or serum aliquots were tailed Student's t test. Apo e allele frequency distribution in frozen and stored at −70°C until analysis. For genotyping, CAPD patients and healthy controls was performed using parallel samples of venous blood were collected in EDTA-the chi-square test. containing tubes and frozen at −70°C.
Plasma lipid and lipoprotein levels were determined in Results fresh plasma samples. Triglycerides and cholesterol were determined using standard enzymatic techniques (Boehringer Mannheim, Mannheim, Germany). HDL cholesterol levels Among the CAPD subjects, total serum and LDL were analysed after precipitation of apo B-containing pro-cholesterol levels were increased and HDL cholesterol levels decreased compared to healthy controls Table 1 . Clinical baseline data on the CAPD subjects (n=51 ) ( Table 2 ) . Also, fasting triglyceride levels were higher among the patients. The distribution of apo E phenoAge ( years) 55±13 (range 30-79 ) types and alleles are given in There was a relatively high relative frequency of the
e4-allele (0.206) and this frequency was similar to the S-urea (mmol/l ) 20.9±6.0 distribution among healthy Swedes.
S-creatinine (mmol/l ) 653±167
As seen in Table 4 , serum total and LDL cholesterol
Haemoglobin (g/l ) 110±23 levels were higher in the E 4/3 and E 4/4-groups impact of variation at the apo e locus on serum lipid levels in CAPD-patients. As treatment regimens are Mean±SD are given for 51 subjects with CAPD. Levels for normals continuously improved among subjects undergoing (mean±SD) are from ref. [17] . Levels are given in mmol/l, and to dialysis treatment for end-stage kidney disease with an convert mmol/l to mg/dl, multiply by 38.7 for cholesterol and 88.5 increased survival time, the possibilities for follow-up for triglycerides. †P<0.0001 compared to normals, data from referare also increasing. It has now become apparent that ence [ 17] . under these conditions, hyperlipidaemia and accelerated atherosclerosis is common [22, 23] . Although cle- with decreased longevity, with a decrease in the apo e4 allele frequency among the elderly [17, 19, 20] . Recently, the apo e4 allele was also associated with compared to the E 3/3 phenotype. In order to allow a comparison between the dominating apo E phenotype Alzheimer's disease [21] . The role of variation at the apo e locus in renal disease is however largely groups, the results for the E 3/3 subjects were directly compared with those for the e4-carriers (E 4/3 and unknown.
The apo e allele distribution in the CAPD subjects 4/4 ). LDL cholesterol levels were significantly higher among the e4-carriers (4.82±1.06 mmol/l vs 3.98± was very similar to the distribution in the healthy population. The absence of overrepresentation of the 1.16 mmol/l for the E 3/3 group, P=0.02), and also total serum cholesterol levels tended to be higher apo e4 allele suggest that it was not intrinsically associated with renal disease. However, as the CAPD in the e4-carriers (7.28±1.26 mmol/l vs 6.49±1.50 mmol/l for the E3/3 group, P=0.079). No significant subjects had high mean total and LDL cholesterol levels, the impact of additional risk factors on serum differences were seen for HDL cholesterol or serum triglyceride levels between the two groups.
lipid levels, such as presence of the e4 allele may be particularly pronounced in this population. Indeed, in Among the twelve subjects with established cardiovascular disease (CAD), the allele frequency of the spite of the heterogeneity of the CAPD patients and the somewhat limited number of subjects in the present e4-allele was 0.291, compared to a frequency of 0.179 among subjects without CAD. In contrast, the e3-allele study compared to population studies, we could dem- Serum lipid levels are given as mmol/l and expressed as means±SD. To convert to mg/dl, multiply by 38.7 for cholesterol and 88.5 for triglycerides.
11. Cumming AM, Robertson FW. Polymorphism at the onstrate a clearly significant increase in the levels of apolipoprotein-E locus in relation to risk of coronary disease.
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